Supernus Pharmaceuticals (NASDAQ:SUPN) Issues Earnings Results, Beats Estimates By $0.25 EPS

Supernus Pharmaceuticals (NASDAQ:SUPN) released its quarterly earnings results on Monday. The specialty pharmaceutical company reported $0.69 EPS for the quarter, topping the consensus estimate of $0.44 by $0.25, Briefing.com reports. The business had revenue of $175.70 million during the quarter, compared to analyst estimates of $157.35 million. Supernus Pharmaceuticals had a net margin of 0.83% and a return on equity of 0.56%. The company’s quarterly revenue was up 14.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.29) earnings per share. Supernus Pharmaceuticals updated its FY 2024 guidance to EPS.

Supernus Pharmaceuticals Price Performance

SUPN opened at $34.70 on Tuesday. The business has a 50-day moving average of $33.02 and a 200-day moving average of $30.46. Supernus Pharmaceuticals has a fifty-two week low of $23.05 and a fifty-two week high of $35.56. The company has a market capitalization of $1.91 billion, a PE ratio of 385.56 and a beta of 0.86.

Analysts Set New Price Targets

SUPN has been the topic of a number of research analyst reports. Piper Sandler reissued a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Finally, StockNews.com upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.